Our ability to sequence genomes, essentially identifying all components of our DNA, combined with big data analysis and technologies that will allow us to edit DNA, portend profound implications for generational health and well-being.
The impact on family members, family dynamics, and family offices is inestimable.
The wealthy have a unique opportunity to become hyperagents of change. Trustees and advisors will have fiduciary responsibility to assist their clients negotiating these deeply personal technologies, which raise unpredictable questions and ethical quandaries.
Family offices must employ a bespoke approach, incorporating personal values, mores, culture, and the law, all essential components of decision-making in this new world of reading and writing biology.
The summit represents the beginning of necessary critical conversation and planning for imminent disruptive technology, and offers unique opportunity to dialogue with scientists of the highest caliber and other global families.
Professor of Health Sciences and Technology at Harvard University and the Massachusetts Institute of Technology





- the evolving landscape of genomic technologies
- gene editing in humans
- the role of genomics in brain and behavior, reproductive technologies, and aging
- investment and entrepreneurial opportunities in the genetics industry
- philanthropic possibilities that will arise from family knowledge of genetic makeup
- ongoing discussion will be facilitated throughout the day to address ethical, moral, social, legal, and privacy complexities inherent in the application of these new technologies, matters critically relevant to families of wealth
- Ting Wu, Ph.D.
- Ronnie S. Stangler, M.D.
- Personal Genetics Education Project (pgEd)
- Howard Cooper – Cooper Family Office, Palm Beach, FL
- Judy L. Green – President, Family Firm Institute, Boston, MA
- Alexander Hayward – Wealth Strategist, Private Office Consultant, London, U.K.
Lazard Asset Management and Asclepius Life Sciences,
for their generous support of the Summit.